Clinical trials: Aripiprazole
Schizophrenia
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
- Trial name
- NCT02634320
- Testing
- Aripiprazole Lauroxil
- Where
- 18 sites in United States
- Volunteers
- 51 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.
- Trial name
- NCT03345979
- Testing
- Aripiprazole Lauroxil, Paliperidone Palmitate
- Where
- 16 sites in United States
- Volunteers
- 200 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-
The objective of this study is to examine the effects of aripiprazole on glucose metabolism in schizophrenic patients without hyperglycemia and diabetes mellitus or any history thereof.
- Trial name
- NCT00392197
- Testing
- Aripiprazole
- Where
- 5 sites in Japan
- Volunteers
- 111 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.
- Trial name
- ASPIRE (NCT00705783)
- Testing
- Aripiprazole depot
- Where
- 110 sites in United States, Argentina and 10 more
- Volunteers
- 843 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette's Disorder, Tic Disorder
Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current trial is to determine efficacy and safety of Once-daily aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01727700
- Testing
- Aripiprazole
- Where
- 75 sites in United States, Canada and 7 more
- Volunteers
- 133 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autistic Disorder
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
The Biomarkers in autism of aripiprazole and risperidone treatment (BAART) project will provide evidence-based guidance in the selection and monitoring of drug treatment of autism.
- Trial name
- BAART (NCT01333072)
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medical University of South Carolina
Tourette's Disorder
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)
The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01418352
- Testing
- Aripiprazole
- Where
- 35 sites in United States, Bulgaria and 3 more
- Volunteers
- 83 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alcohol Dependence
Aripiprazole Effects on Alcohol Drinking and Craving
The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer) is effective in reducing of alcohol craving and drinking compared to placebo depending on participant's baseline level of impulsivity.
- Trial name
- NCT01292057
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Medical University of South Carolina
Schizophrenia
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia
- Trial name
- NCT02054702
- Testing
- Brexpiprazole, Aripiprazole
- Volunteers
- 97 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Sexual Dysfunction
Aripiprazole, Abilify Maintena Collaborative Clinical Protocol
Sexual dysfunction is highly prevalent in schizophrenic patients, affecting up to 80% of men and women. Antipsychotic induced sexual side effects may be a barrier to treatment compliance.
- Trial name
- KISS (NCT02472652)
- Testing
- Abilify Maintena
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Gazda, Thomas D., M.D., PC
Schizophrenia
Switching Medication to Treat Schizophrenia
This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
- Trial name
- NCT00044655
- Testing
- Risperidone, Olanzapine, Ziprasidone
- Volunteers
- 219 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Schizophrenia
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
The primary objective of this study was to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical…
- Trial name
- NCT00845026
- Testing
- LY2140023, aripiprazole, olanzapine
- Where
- 23 sites in United States, Germany and 2 more
- Volunteers
- 261 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia
This study is being conducted to find a way to predict how individual schizophrenic patients will respond if they are treated with different types of antipsychotic drugs.
- Trial name
- BEST (NCT00712270)
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Kettering Health Network
Schizophrenia
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
The purpose of this study is to determine whether weight gain will be significantly less in LY2140023 than aripiprazole in patients with schizophrenia.
- Trial name
- NCT01328093
- Testing
- LY2140023, Aripiprazole
- Where
- 51 sites in United States, Austria and 8 more
- Volunteers
- 678 people
- Sponsor
- Denovo Biopharma LLC
Conduct Disorder
Trial of Aripiprazole in the Treatment of CD in Adolescents
The proposed study will be a 6-week open label study evaluating aripiprazole in the treatment of 12 male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder.
- Trial name
- NCT00250705
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Bipolar Disorder
Study of Aripiprazole (Abilify) in Children With Symptoms of Mania
The purpose of this study is to look at the safety and effectiveness of aripiprazole (abilify) in children with bipolar disorder and to examine whether or not patients that respond to initial mood stabilization benefit from…
- Trial name
- NCT00194077
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia
A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
The primary objective of the study was to determine the safety of aripiprazole administered long-term in doses ranging from 10 to 30 mg per day as a maintenance therapy in subjects with chronic or first episode of schizophrenia.
- Trial name
- NCT02435836
- Testing
- Aripiprazole
- Volunteers
- 631 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autism, Asperger's Disorder
An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders
The aim of this study is to evaluate the efficacy, safety and tolerability of aripiprazole monotherapy in the treatment of children and adolescents suffering from Autism Spectrum Disorder (ASD) over a 12-week period.
- Conditions
- Autism, Asperger's Disorder, Pervasive Developmental Disorder
- Trial name
- NCT00308074
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Cambridge Health Alliance
Major Depressive Disorder
Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.
- Trial name
- NCT02046564
- Testing
- ASC-01
- Where
- 29 sites in Australia, Japan and 3 more
- Volunteers
- 412 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Antipsychotic Effects on Brain Function in Schizophrenia
The purpose of the study is to determine whether two commonly-prescribed antipsychotic medications (aripiprazole and risperidone) have different effects on brain function and cognition in schizophrenia patients.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- APD (NCT01913327)
- Testing
- Aripiprazole, Risperidone, Modafinil
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Francisco